# US 10,869,905 B2 · Composition for treating cellulite, and microneedle including same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,905 B2
- Document ID: US10869905B2
- Status: Granted
- Kind: B2
- Application number: 16/329,553
- Filed: 2017-08-29
- Published: 2019-06-27
- Granted: 2020-12-22
- Earliest claimed: 2016-08-31
- Assignees: Pusan National University Industry-University Cooperation Foundation
- Applicants: Pusan National University Industry-University Cooperration Foundation
- Inventors: Seung Yun Yang; Beum Soo An; Keum Yong Seong; Sung Min An
- Web page: https://patentgrep.com/patent/US10869905B2

## CPC

- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61M 37/0015: {by using microneedles}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/003: {having a lumen}
- A61M 2037/0061: {Methods for using microneedles}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.

## Claims

### Claim 1

A method for treating an individual having localized obesity, the method comprising administering a composition comprising animal-derived gelatin to the individual at a location where the individual has localized obesity,
wherein the composition is administered by injection with a hypodermic needle or with a microneedle to skin tissue below the skin stratum corneum, and
wherein the composition reduces adipocyte size in adipose tissue at the location where the individual has localized obesity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered with the hypodermic needle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the individual is obese.

### Claim 4 (depends on 1)

The method of claim 1, wherein the animal derived gelatin is a swine-derived gelatin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the animal derived gelatin is cross-linked.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cross-linked gelatin is cross-linked with genipin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered with the microneedle.

### Claim 8 (depends on 7)

The method of claim 7, wherein the microneedle comprises a tip portion having a length equal to or greater than a thickness of a skin stratum corneum of the individual.

### Claim 9 (depends on 8)

The method of claim 8, wherein the microneedle is applied onto skin of the individual and at least a portion of the tip portion of the microneedle is located below the skin stratum corneum,
wherein the tip portion comprises the composition, and
wherein the tip portion decomposes at a position below the skin stratum corneum such that the composition is released from the tip portion and locally decomposes adipose tissue and locally inhibits lipogenesis and fat-deposition.

### Claim 10 (depends on 8)

The method of claim 8, wherein the tip portion has a length of 10 μm to 300 μm.

### Claim 11 (depends on 10)

The method of claim 10, wherein the microneedle further comprises a patch layer having a surface on which the tip portion is disposed.

### Claim 12 (depends on 11)

The method of claim 11, wherein the patch layer is in contact with the skin and at least a portion of the tip portion is located below the skin stratum corneum.